OrbusNeich Medical Group Holdings (FRA:Q8T) ROCE % : 11.43% (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is OrbusNeich Medical Group Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OrbusNeich Medical Group Holdings's annualized ROCE % for the quarter that ended in Jun. 2024 was 11.43%.

OrbusNeich Medical Group Holdings ROCE % Historical Data

The historical data trend for OrbusNeich Medical Group Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OrbusNeich Medical Group Holdings ROCE % Chart

OrbusNeich Medical Group Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

2.89

8.25

13.99

11.22

OrbusNeich Medical Group Holdings Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial					8.31	16.39	11.91	11.43	11.03

OrbusNeich Medical Group Holdings ROCE % Calculation

OrbusNeich Medical Group Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	45.632	/	( ( (331.401 - 22.479)	+	(376.102 - 32.667) )	/ 2 )
	=	45.632	/	( (308.922	+	343.435)	/ 2 )
	=	45.632	/	326.1785
	=	13.99 %

OrbusNeich Medical Group Holdings's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	39.782	/	( ( (376.102 - 32.667)	+	(385.939 - 33.362) )	/ 2 )
	=	39.782	/	( ( 343.435	+	352.577 )	/ 2 )
	=	39.782	/	348.006
	=	11.43 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

OrbusNeich Medical Group Holdings (FRA:Q8T) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OrbusNeich Medical Group Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OrbusNeich Medical Group Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (FRA:Q8T) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

06929:Hong Kong

Address

3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG

Website

https://www.orbusneich.com

OrbusNeich Medical Group Holdings Ltd is a China-based medical device maker of endovascular interventional instruments with majority reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's majority revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.

OrbusNeich Medical Group Holdings Headlines

No Headlines